Amgen’s Tepezza granted marketing authorisation in the UK
8th May 2025 Uncategorised 0
Teprotumumab approved as first targeted treatment for thyroid eye disease

More: Amgen’s Tepezza granted marketing authorisation in the UK
Source: News
Teprotumumab approved as first targeted treatment for thyroid eye disease

More: Amgen’s Tepezza granted marketing authorisation in the UK
Source: News
© 1994 - 2026 B.M. Pharmaceuticals